当前位置:产品中心>单抗/多抗

Anti-HRSV Fusion Protein Reference Antibody|抗HRSV融合蛋白参考抗体(靶标:人呼吸道合胞病毒融合蛋白)

货号:RB9T37015295
  • 价格:面议
  • 点击数:640
  

产品介绍

产品参数

产品描述Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).
形态Liquid
宿主种属Humanized
克隆性Monoclonal
抗体亚型IgG1, kappa
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性HRSV-A
靶标F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号P03420
背景信息Palivizumab (brand name Synagis) is a humanized IgG monoclonal antibody (mAb) manufactured by MedImmune with recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab directed against an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cκ and the variable framework regions of the VL gene K104 with Jκ -4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy chains and two light chains and has a molecular weight of approximately 148, 000 Daltons. Palivizumab was approved for medical use in 1998 but the indications for prophylaxis vary worldwide. Palivizumab is primarily indicated for the following conditions: prematurity (gestational age ≤ 35 weeks), bronchopulmonary dysplasia/chronic lung disease, hemodynamically significant congenital heart disease, and other serious medical disorders on an ad hoc basis. Infants with these medical conditions are at increased risk of more severe disease and more serious subsequent sequelae.<br>
别名SB209763, HuRSV19VHFNS/VK, RSHZ19monoclonalantibody, SB209763, 167747-20-8
备注For research use only. Not suitable for clinical or therapeutic use.